Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among premenopausal women with ER-positive disease who received ovarian suppression, according to a ...

The derived benefit from aromatase inhibitors was typically observed in treatment years 0 to four. Limited follow-up remains beyond the 10-year mark. “Using (aromatase inhibitors) rather than ...

Aromatase inhibitors inhibit the natural production of estrogen by blocking aromatase, an enzyme required for generating the hormone.These drugs are typically used to treat postmenopausal women.

• Aromatase inhibitors reduce the risk of breast cancer recurrence by up to a third compared with tamoxifen. • These drugs are as effective in women under 35, who have a higher risk of ...

Hormone therapy for breast cancer – such as tamoxifen and aromatase inhibitors – can help prevent the cancer from coming back. If you have side effects, these things may help.

Sept 19, 2005. Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T ...

Older woman looking at bottle of pills. Aromatase inhibitors improved disease-free survival when compared with tamoxifen in HR+, HER2- early breast cancer, regardless of menopausal status.

Switching treatment to exemestane after 2–3 years on tamoxifen, improves disease-free survival and seems to modestly reduce risk of death, according to an online article published today, Tuesday ...

Women who switch from the breast cancer pill tamoxifen to a newer class of drugs called aromatase inhibitors live longer, Italian researchers reported. IE 11 is not supported. For an optimal ...

Aromatase inhibitors may reduce breast cancer recurrence compared with tamoxifen for certain postmenopausal women with breast cancer, according to study results presented at San Antonio Breast ...

Show More Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada However, it is well known that women with a previous diagnosis of breast cancer have a long-term ongoing risk of breast ...

Overall, treatment for 5 years with aromatase inhibitors was associated with a non–statistically significant increased odds of death, without disease recurrence, vs 5 years of tamoxifen alone or ...